Drug Class Description

Generic Name

Drug Description

Presentation

Indications

Adult Dosage

Cetrotide 3 mg should only be prescribed by a specialist experienced in this field.

Cetrotide 3 mg is for subcutaneous injection into the lower abdominal wall.

The first administration of Cetrotide should be performed under the supervision of a physician and under conditions where treatment of possible pseudo-allergic reactions is immediately available. The following injections may be self-administered as long as the patient is made aware of the signs and symptoms that may indicate hypersensitivity, the consequences of such a reaction and the need for immediate medical intervention. The contents of 1 vial (3 mg cetrorelix) are to be administered on day 7 of ovarian stimulation (approximately 132 to 144 hours after start of ovarian stimulation) with urinary or recombinant gonadotropins. Following the first administration, it is advised that the patient be kept under medical supervision for 30 minutes to ensure there is no allergic/pseudo-allergic reaction to the injection. Facilities for the treatment of such reactions should be immediately available.

If the follicle growth does not allow ovulation induction on the fifth day after injection of Cetrotide 3 mg, additionally 0.25 mg cetrorelix (Cetrotide 0.25 mg) should be administered once daily beginning 96 hours after the injection of Cetrotide 3 mg until the day of ovulation induction.

Child Dosage

Elderly Dosage

Contra Indications

• Hypersensitivity to the active substance or any structural analogue of GnRH, extrinsic peptide hormones or to any of the excipients.
• Pregnancy, and lactation.
• Postmenopausal women.
• Patients with moderate and severe renal and hepatic impairment.

.

Special Precautions

Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. Treatment with Cetrotide is not advised in women with severe allergic conditions.

During or following ovarian stimulation an ovarian hyperstimulation syndrome can occur. This event must be considered as an intrinsic risk of the stimulation procedure with gonadotropins.

An ovarian hyperstimulation syndrome should be treated symptomatically, e.g. with rest, intravenous electrolytes/colloids and heparin therapy.

Luteal phase support should be given according to the reproductive medical centre´s practice.

There is limited experience up to now with the administration of Cetrotide 3 mg during a repeated ovarian stimulation procedure. Therefore Cetrotide 3 mg should be used in repeated cycles only after a careful risk/benefit eva luation.

Interactions

In vitro investigations have shown that interactions are unlikely with medications that are metabolised by cytochrome P450 or glucuronised or conjugated in some other way. However, interactions with commonly used medicinal products, including products that may induce histamine release in susceptible individuals, may occur.

Adverse Reactions

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Manufacturer

Drug Availability

Updated